Display options
Cite
Al-Kawaaz M, Sanchez T, Kluk MJ. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. J Hematop. 2019;12(2):57-65doi: 10.1007/s12308-019-00354-y.
Al-Kawaaz, M., Sanchez, T., & Kluk, M. J. (2019). Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. Journal of hematopathology, 12(2), 57-65. https://doi.org/10.1007/s12308-019-00354-y
Al-Kawaaz, Mustafa, et al. "Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas." Journal of hematopathology vol. 12,2 (2019): 57-65. doi: https://doi.org/10.1007/s12308-019-00354-y
Al-Kawaaz M, Sanchez T, Kluk MJ. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. J Hematop. 2019 Jun;12(2):57-65. doi: 10.1007/s12308-019-00354-y. Epub 2019 Apr 27. PMID: 31404445; PMCID: PMC6688509.
Copy Download .nbib Format: NLM
Share it on

J Hematop. 2019 Jun;12(2):57-65. doi: 10.1007/s12308-019-00354-y. Epub 2019 Apr 27.

Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.

Journal of hematopathology

Mustafa Al-Kawaaz, Teresa Sanchez, Michael J Kluk

Affiliations

  1. Weill Cornell Medicine, Dept. of Pathology and Laboratory Medicine New York, NY, USA.
  2. Weill Cornell Medicine, Dept. of Neuroscience, Brain and Mind Research Institute, New York, NY, USA.

PMID: 31404445 PMCID: PMC6688509 DOI: 10.1007/s12308-019-00354-y

Abstract

BACKGROUND: Aggressive, mature B-cell lymphomas include Burkitt Lymphoma (BL), High Grade B Cell Lymphomas (HGBL) (eg, Double-Hit B cell lymphomas (HGBL-DH: HGBL with MYC and BCL2 and/or BCL6 translocations)), HGBL, Not Otherwise Specified (HGBL, NOS) and Diffuse Large B Cell Lymphoma (DLBCL). Overlapping morphologic and immunohistochemical features of these lymphomas pose diagnostic challenges in some cases, and better understanding of potential diagnostic biomarkers and possible therapeutic targets is needed. Sphingosine 1 Phosphate Receptors (S1PR1-5) are G-protein coupled receptors that bind S1P and influence migration and survival in multiple cell types, including lymphocytes. S1PRs are emerging as biomarkers in B cell biology and interaction between S1PR pathways and STAT3 or FOXP1 has been reported in DLBCL.

AIM AND METHODS: Our aim was to extend the understanding of S1PR1, STAT3 and S1PR2, FOXP1 expression beyond DLBCL, into additional aggressive, mature B cell lymphomas using immunohistochemical expression analysis of human tissue samples.

RESULTS: S1PR1 and S1PR2 showed different expression patterns in mantle zones and follicle centers in reactive lymphoid tissue. BL showed a unique expression pattern compared to HGBL and DLBCL. Additionally, S1PR1 and S1PR2 expression were typically mutually exclusive and were expressed in a low proportion of cases (frequently HGBL involving extranodal sites). FOXP1 was expressed in a high proportion of various case types and pSTAT3 was detected in a significant proportion of HGBL and DLBCL.

CONCLUSIONS: These findings provide further evidence that S1PR1, pSTAT3, S1PR2 and FOXP1 play a role in a subset of aggressive, mature B cell lymphomas.

Keywords: FOXP1; S1P; S1PR; Sphingosine-1-Phosphate; lymphoma; pSTAT3

Conflict of interest statement

Conflict of Interest: MAK, TS and MJK declare that they have no conflict of interest.

References

  1. Blood. 2008 Feb 1;111(3):1515-23 - PubMed
  2. Blood. 2008 Apr 1;111(7):3701-13 - PubMed
  3. Cancer Res. 2009 Nov 15;69(22):8686-92 - PubMed
  4. Mod Pathol. 2010 Mar;23(3):439-49 - PubMed
  5. Nat Med. 2010 Dec;16(12):1421-8 - PubMed
  6. Mod Pathol. 2011 Sep;24(9):1248-53 - PubMed
  7. Nat Immunol. 2011 Jun 05;12(7):672-80 - PubMed
  8. J Hematol Oncol. 2011 Aug 01;4(1):31 - PubMed
  9. Blood. 2012 Aug 16;120(7):1458-65 - PubMed
  10. Lab Invest. 2013 Apr;93(4):462-71 - PubMed
  11. Blood. 2013 Aug 15;122(7):1256-65 - PubMed
  12. J Clin Oncol. 2013 Dec 20;31(36):4520-8 - PubMed
  13. Clin Cancer Res. 2014 Oct 1;20(19):5113-23 - PubMed
  14. Nature. 2014 Dec 11;516(7530):254-8 - PubMed
  15. BMC Cancer. 2014 Dec 03;14:911 - PubMed
  16. Am J Surg Pathol. 2015 Aug;39(8):1132-9 - PubMed
  17. Exp Hematol Oncol. 2015 Apr 01;4:10 - PubMed
  18. Blood. 2016 Mar 17;127(11):1438-48 - PubMed
  19. Br J Haematol. 2016 Jul;174(2):264-74 - PubMed
  20. Curr Atheroscler Rep. 2016 Jun;18(6):31 - PubMed
  21. Leuk Lymphoma. 2017 May;58(5):1037-1051 - PubMed
  22. Histol Histopathol. 2017 Aug;32(8):825-834 - PubMed
  23. Biochem Biophys Res Commun. 2017 Jun 17;488(1):182-188 - PubMed
  24. Sci Rep. 2017 May 8;7(1):1566 - PubMed
  25. Leukemia. 2018 Jan;32(1):214-223 - PubMed
  26. Oncotarget. 2017 Oct 31;8(57):97516-97527 - PubMed
  27. Blood Adv. 2018 Mar 27;2(6):621-625 - PubMed
  28. Blood. 2018 Apr 26;131(17):1920-1930 - PubMed

Publication Types

Grant support